Abstract:The endogenous opioid system regulates pain through local release of neuropeptides and modulation of their action on opioid receptors. However, the effect of opioid peptides, the enkephalins, is short-lived due to their rapid hydrolysis by enkephalin-degrading enzymes. In turn, an innovative approach to the management of pain would be to increase the local concentration and prolong the stability of enkephalins by preventing their inactivation by neural enkephalinases such as puromycin sensitive aminopeptidase (PSA). Our previous structure-activity relationship studies offered the S-diphenylmethyl cysteinyl derivative of puromycin ( ) as a nanomolar inhibitor of PSA. This chemical class, however, suffered from undesirable metabolism to nephrotoxic puromycin aminonucleoside (PAN). To prevent such toxicity, we designed and synthesized 5′-chloro substituted derivatives. The compounds retained the PSA inhibitory potency of the corresponding 5′-hydroxy analogs and had improved selectivity toward PSA. In vivo treatment with the lead compound caused significantly reduced pain response in antinociception assays, alone and in combination with Met-enkephalin. The analgesic effect was reversed by the opioid antagonist naloxone, suggesting the involvement of opioid receptors. Further, PSA inhibition by compound in brain slices caused local increase in endogenous enkephalin levels, corroborating our rationale. Pharmacokinetic assessment of compound showed desirable plasma stability and identified the cysteinyl sulfur as the principal site of metabolic liability. We gained additional insight into inhibitor-PSA interactions by molecular modeling, which underscored the importance of bulky aromatic amino acid in puromycin scaffold. The results of this study strongly support our rationale for the development of PSA inhibitors for effective pain management.

Interplay between the Endogenous Opioid System and Proteasome Complex: Beyond Signaling

The Roles of Ubiquitin-Proteasome System and Regulator of G Protein Signaling 4 in Behavioral Sensitization Induced by a Single Morphine Exposure

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Profiling the proximal proteome of the activated μ-opioid receptor

The opioid receptors as targets for drug abuse medication

Modulation of endogenous opioid signaling by inhibitors of puromycin sensitive aminopeptidase

Mu-opioid receptor and receptor tyrosine kinase crosstalk: Implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward

Untangling the complexity of opioid receptor function

Opioid system and related ligands: from the past to future perspectives

The role of the ubiquitin system in the onset and reversal of neuropathic pain

Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR Review 10

Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors

Reward processing by the opioid system in the brain

Receptor Trafficking Induced by Mu-Opioid-Receptor Phosphorylation

Integrated Systems Analysis of Mixed Neuroglial Cultures Proteome Post Oxycodone Exposure

Endomorphins: Potential Roles and Therapeutic Indications in the Development of Opioid Peptide Analgesic Drugs

Chronic Morphine Treatment Induces Over-Expression of HSP70 in Mice Striatum Related with Abnormal Ubiquitin-Proteasome Degradation.

Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors

Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management

Opioid Signal Transduction Regulates The Dendritic Morphology Of Somatostatin And Parvalbumin Interneurons In The Medial Prefrontal Cortex

Molecular basis of opioid receptor signaling